# TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

> **NCT01192022** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 253 (actual)

## Conditions studied

- Hemorrhage

## Interventions

- **BIOLOGICAL:** TachoSil®
- **DEVICE:** Surgicel® Original

## Key facts

- **NCT ID:** NCT01192022
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2015-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192022, "TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01192022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*